LindeboomRGH, VermeulenM, LehnerB, SupekF: The impact of nonsense-mediated mRNA decay on genetic disease, gene editing and cancer immunotherapy. Nat Genet, 2019; 51:1645–1651.
2.
HuangY, YanJ, LiQ, et al.: Meclofenamic acid selectively inhibits FTO demethylation of m6A over ALKBH5. Nucleic Acids Res, 2015; 43:373–384.
3.
Belin-RauscentA, LacosteJ, HermineO, MoussyA, EverittBJ, BelinD: Decrease of cocaine, but not heroin, self-administration and relapse by the tyrosine kinase inhibitor masitinib in male Sprague Dawley rats. Psychopharmacology (Berl), 2018; 235:1545–1556.
4.
SchiffM, RodaC, MoninML, et al.: Clinical, laboratory and molecular findings and long-term follow-up data in 96 French patients with PMM2-CDG (phosphomannomutase 2-congenital disorder of glycosylation) and review of the literature. J Med Genet, 2017; 54:843–851.
Martinez-MonsenyAF, BolaselliM, Callejón-Póo, et al.: AZATAX: acetazolamide safety and efficacy in cerebellar syndrome in PMM2 congenital disorder of glycosylation (PMM2-CDG). Ann Neurol, 2019; 85:740–751.
7.
IyerS, SamFS, DiPrimioN, et al.: Repurposing the aldose reductase inhibitor and diabetic neuropathy drug epalrestat for the congenital disorder of glycosylation PMM2-CDG. Dis Model Mech, 2019; 12:dmm040584.
8.
TillyBC, TertoolenLG, RemorieR, et al.: Histamine as a growth factor and chemoattractant for human carcinoma and melanoma cells: action through Ca2(+)-mobilizing H1 receptors. J Cell Biol, 1990; 110:1211–1215.
9.
DöbbelingU, Waeckerle-MenY, ZabelF, et al.: The antihistamines clemastine and desloratadine inhibit STAT3 and c-Myc activities and induce apoptosis in cutaneous T-cell lymphoma cell lines. Exp Dermatol, 2013; 22:119–124.
10.
FritzI, WagnerP, OlssonH: Improved survival in several cancers with use of H1-antihistamines desloratadine and loratadine. Transl Oncol, 2021; 14:101029.
11.
BairMJ, KrebsEE: Fibromyalgia. Ann Intern Med, 2020; 172:ITC33–ITC48.
12.
MetyasS, RezkT, ArkfeldD, LeptichT: Autoinflammation and immunomodulation in inflammatory fibromyalgia syndrome—a review. Curr Rheumatol Rev, 2017; 13:98–102.
MorfS, Amann-VestiB, ForsterA, et al.: Microcirculation abnormalities in patients with fibromyalgia—measured by capillary microscopy and laser fluxmetry. Arthritis Res Ther, 2005; 7:R209–R216.
15.
LindhM, JohanssonG, HedbergM, HenningGB, GrimbyG: Muscle fiber characteristics, capillaries and enzymes in patients with fibromyalgia and controls. Scand J Rheumatol, 1995; 24:34–37.
16.
AmbergN, SotiropoulouPA, HellerG, et al.: EGFR controls hair shaft differentiation in a p53-independent manner. iScience, 2019; 15:243–256.
17.
CampbellP, MortonPE, TakeichiT, et al.: Epithelial inflammation resulting from an inherited loss-of-function mutation in EGFR. J Invest Dermatol, 2014; 134:2570–2578.
18.
ZhengH, ZhangH, ZhangT, WangQ, HuF, LiB: Trichomegaly and scalp hair changes following treatment with erlotinib in pulmonary adenocarcinoma patients: a case report and literature review. Exp Ther Med, 2016; 12:1287–1292.
19.
BichselKJ, GogiaN, MalouffT, et al.: Role for the epidermal growth factor receptor in chemotherapy-induced alopecia. PLoS One, 2013; 8:e69368.
20.
GeraghtyAC, GibsonEM, GhanemRA, et al.: Loss of adaptive myelination contributes to methotrexate chemotherapy-related cognitive impairment. Neuron, 2019; 103:250–265.e8.
21.
ZhouX, HeC, RenJ, et al.: Mature myelin maintenance requires Qki to coactivate PPARβ-RXRα-mediated lipid metabolism. J Clin Invest, 2020; 130:2220–2236.
22.
ChiangACA, SeuaAV, SinghmarP, et al.: Bexarotene normalizes chemotherapy-induced myelin decompaction and reverses cognitive and sensorimotor deficits in mice. Acta Neuropathol Commun, 2020; 8:193.
23.
FairweatherD, Frisancho-KissS: Mast cells and inflammatory heart disease: potential drug targets. Cardiovasc Hematol Disord Drug Targets, 2008; 8:80–90.
24.
JulianoGR, SkafMF, RamalhoLS, et al.: Analysis of mast cells and myocardial fibrosis in autopsied patients with hypertensive heart disease. Rev Port Cardiol (Engl Ed), 2020; 39:89–96.
25.
YoshimaruT, SuzukiY, InoueT, RaC: L-type Ca2+ channels in mast cells: activation by membrane depolarization and distinct roles in regulating mediator release from store-operated Ca2+ channels. Mol Immunol, 2009; 46:1267–1277.
26.
TangL, WuY, TianM, et al.: Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes. Am J Physiol Endocrinol Metab, 2017; 313:E563–E576.
27.
KajiK, NishimuraN, SekiK, et al.: Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake. Int J Cancer, 2018; 142:1712–1722.
28.
JojimaT, WakamatsuS, KaseM, et al.: The SGLT2 inhibitor canagliflozin prevents carcinogenesis in a mouse model of diabetes and non-alcoholic steatohepatitis-related hepatocarcinogenesis: association with SGLT2 expression in hepatocellular carcinoma. Int J Mol Sci, 2019; 20:5237.
29.
WeissJ, HaefeliWE: Potential of the novel antiretroviral drug rilpivirine to modulate the expression and function of drug transporters and drug-metabolising enzymes in vitro. Int J Antimicrob Agents, 2013; 41:484–487.
30.
HechtM, ErberS, HarrerT, et al.: Efavirenz has the highest anti-proliferative effect of non-nucleoside reverse transcriptase inhibitors against pancreatic cancer cells. PLoS One, 2015; 10:e0130277.
31.
CavalliG, DinarelloCA: Anakinra therapy for non-cancer inflammatory diseases. Front Pharmacol, 2018; 9:1157.
MasoudY, RaminS, MahboobehR, MehrnooshM, FahimehJ, ParastooK: Effect of lithium and valproate on proliferation and migration of limbal epithelial stem/progenitor cells. Curr Eye Res, 2019; 44:154–161.
34.
LiuS, LiuL, JinD, ZhangQ, TakaiS: The novel mechanism of valproate to prevent peritoneal adhesion formation. Surg Today, 2020; 50:1091–1098.
35.
XiongW, LuL, ZhangY, et al.: Attenuation of retinal nerve fibre layer in people with epilepsy receiving valproate. Epilepsy Res, 2019; 154:144–148.
36.
MahalingamK, ChaurasiaAK, GowthamL, et al.: Therapeutic potential of valproic acid in advanced glaucoma: a pilot study. Indian J Ophthalmol, 2018; 66:1104–1108.
37.
SeetLF, TohLZ, FingerSN, ChuSW, StefanovicB, WongTT: Valproic acid suppresses collagen by selective regulation of Smads in conjunctival fibrosis. J Mol Med (Berl), 2016; 94:321–334.
38.
HuangF, ZhangH, WuM, et al.: Calcium-activated chloride channel TMEM16A modulates mucin secretion and airway smooth muscle contraction. Proc Natl Acad Sci U S A, 2012; 109:16354–16359.
39.
MinerK, LabitzkeK, LiuB, et al.: Drug repurposing: the anthelmintics niclosamide and nitazoxanide are potent TMEM16A antagonists that fully bronchodilate airways. Front Pharmacol, 2019; 10:51.
40.
SchreiberR, BuchholzB, KrausA, et al.: Lipid peroxidation drives renal cyst growth in vitro through activation of TMEM16A. J Am Soc Nephrol, 2019; 30:228–242.
